Welcome to our dedicated page for Rallybio news (Ticker: RLYB), a resource for investors and traders seeking the latest updates and insights on Rallybio stock.
Rallybio Corp (RLYB) is a clinical-stage biotechnology company pioneering therapies for severe rare disorders through advanced modalities including antibodies and engineered proteins. This dedicated news hub provides investors and industry observers with essential updates on the company's scientific progress and operational developments.
Access timely reports on clinical trial milestones, regulatory submissions, and strategic collaborations. Our curated collection features verified press releases, financial disclosures, and analysis of RLYB's innovative pipeline targeting conditions like fetal/neonatal alloimmune thrombocytopenia.
Key updates include progress on therapeutic candidates, partnership announcements with research institutions, and financial performance summaries. The resource is particularly valuable for tracking Rallybio's unique approach combining validated biological mechanisms with novel treatment strategies.
Bookmark this page for streamlined access to Rallybio's latest advancements in rare disease research. Check regularly for authoritative reporting on clinical developments and corporate announcements from this innovative biopharma leader.
Rallybio (NASDAQ:RLYB) reported Q2 2025 financial results and significant business updates. The company sold its interest in REV102 to Recursion Pharmaceuticals for up to $25 million, including a $7.5 million upfront equity payment. The deal extends cash runway into mid-2027.
Key financial metrics include a net loss of $9.7 million ($0.22 per share), reduced from $16.2 million in Q2 2024. R&D expenses decreased to $6.1 million from $12.9 million year-over-year. Cash position stands at $45.7 million as of June 30, 2025.
The company's lead program RLYB116 entered a confirmatory PK/PD study, with data readouts expected in Q3 and Q4 2025. However, Rallybio discontinued the RLYB212 program for FNAIT prevention due to inadequate dose concentration achievements in Phase 2 trials.
Rallybio (Nasdaq: RLYB) has agreed to sell its interest in REV102, a preclinical ENPP1 inhibitor program for hypophosphatasia (HPP), to Recursion Pharmaceuticals. The deal is valued at up to $25 million, including a $7.5 million upfront equity payment.
The transaction includes potential milestone payments of $12.5 million for initiating additional preclinical studies and $5 million for Phase 1 clinical study initiation. Rallybio will also receive low single-digit royalties on future net sales. The upfront payment extends Rallybio's cash runway into mid-2027.
REV102, developed through a joint venture between both companies, represents the first potential oral disease-modifying treatment for HPP and entered IND-enabling studies in early 2025.
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotech company focused on developing treatments for rare diseases, has announced an upcoming presentation at the 2025 Citizens JMP Life Sciences Conference.
Key details:
- Speaker: Stephen Uden, M.D., Chief Executive Officer
- Format: Fireside chat
- Date: Wednesday, May 7, 2025
- Time: 12:00 p.m. ET
- Location: New York, NY
The presentation will be available through a live webcast on the Events and Presentations section of Rallybio's website (www.rallybio.com). Investors and interested parties can access a replay of the webcast for 30 days after the presentation.
Rallybio (NASDAQ: RLYB) has announced the discontinuation of its RLYB212 program for preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The decision follows Phase 2 clinical trial results showing the drug's inability to achieve required target concentrations for efficacy.
The company will now focus on advancing RLYB116, a once-weekly C5 inhibitor for complement-driven diseases, with a confirmatory PK/PD study planned for Q2 2025 and data expected in 2H 2025. This program targets diseases including PNH, APS, and gMG, representing a >$6 billion commercial opportunity.
Additionally, Rallybio's pipeline includes REV102, an ENPP1 inhibitor for hypophosphatasia entering IND-enabling studies, and RLYB332, a long-acting matriptase-2 antibody for iron overload diseases.
Rallybio (NASDAQ: RLYB) reported its Q4 and full year 2024 financial results, highlighting key developments and upcoming milestones. The company ended 2024 with $65.5 million in cash and equivalents, providing runway into 2H 2026.
Key financial metrics include Q4 2024 revenue of $38,000 and full-year revenue of $0.6 million, primarily from a Johnson & Johnson collaboration. Q4 net loss was $11.0 million ($0.25 per share), while full-year net loss reached $57.8 million ($1.33 per share).
Notable pipeline updates include:
- RLYB212: Phase 2 trial dosing underway with key data expected in Q2/Q3 2025
- RLYB116: Confirmatory PK/PD study initiation planned for Q2 2025
- REV102: Advancing toward Phase 1 in 2026 for hypophosphatasia treatment
- RLYB332: Showed promising preclinical results for iron overload diseases
Rallybio (Nasdaq: RLYB), a clinical-stage biotechnology company focused on developing therapies for rare diseases, has announced that its Chief Executive Officer, Stephen Uden, M.D., will deliver a corporate overview at the TD Cowen 45th Annual Health Care Conference.
The presentation is scheduled for Tuesday, March 4, 2025 at 1:10 p.m. EST in Boston, MA. Investors and interested parties can access a live webcast of the presentation through the Events and Presentations section of Rallybio's website at www.rallybio.com.
A replay of the webcast will remain available for 30 days following the presentation, allowing those unable to attend the live event to review the company's updates.
Rallybio (RLYB) has initiated dosing in its Phase 2 clinical trial of RLYB212, targeting pregnant women at higher risk for HPA-1a alloimmunization and fetal and neonatal alloimmune thrombocytopenia (FNAIT). The trial will evaluate pharmacokinetics and safety across three stages: a sentinel participant, followed by two cohorts totaling eight participants.
The study involves subcutaneous administration of RLYB212 starting at Gestational Week 16 and continuing every 4 weeks through delivery. Key data readouts are expected in Q2 2025 for second trimester pharmacokinetic and safety data, and Q3 2025 for delivery-time data. The trial will be conducted at European sites.
Rallybio (RLYB) outlined its 2024 achievements and 2025 milestones for its rare disease therapeutics pipeline. The company highlighted progress across multiple programs:
For RLYB212, they initiated the first Phase 2 trial for FNAIT prevention, screened over 14,000 pregnant women, and published Phase 1b results. The RLYB116 program completed manufacturing improvements for better tolerability. Their REV102 program for hypophosphatasia (HPP) treatment advanced, with data showing 30% reduction in PPi biomarker.
Key anticipated 2025 milestones include: RLYB212 Phase 2 trial sentinel participant dosing in Q2 2025 with data readouts in Q3-Q4; RLYB116 confirmatory PK/PD study initiation in Q2 2025 with results in H2 2025; and REV102's progression to IND-enabling studies for Phase 1 initiation in 2026.
FAQ
What is the current stock price of Rallybio (RLYB)?
What is the market cap of Rallybio (RLYB)?
